Stockscreener 앱 받기
34.77
11.59%
3.61
시장 영업 전:
35.73
0.96
+2.76%
전일 마감가:
$31.16
열려 있는:
$33.79
하루 거래량:
79,121
Relative Volume:
1.27
시가총액:
$1.69B
수익:
$32.72M
순이익/손실:
$-27.55M
주가수익비율:
-60.81
EPS:
-0.5718
순현금흐름:
$-41.40M
1주 성능:
+4.98%
1개월 성능:
+12.02%
6개월 성능:
+75.96%
1년 성능:
+882.20%
1일 변동 폭
$33.10
$34.78
1주일 범위
$30.30
$35.94
52주 변동 폭
$3.26
$41.89
나노바이오틱스 Stock (NBTX) Company Profile
Compare NBTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
34.77 | 1.69B | 32.72M | -27.55M | -41.40M | -0.5718 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
나노바이오틱스 Stock (NBTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-06 | 개시 | TD Cowen | Buy |
| 2024-08-28 | 개시 | Guggenheim | Buy |
| 2023-12-08 | 개시 | Leerink Partners | Outperform |
| 2021-01-06 | 개시 | Evercore ISI | Outperform |
나노바이오틱스 주식(NBTX)의 최신 뉴스
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study - ChartMill
NBTX Forecast, Price Target & Analyst Ratings | NANOBIOTIX SAADR (NASDAQ:NBTX) - ChartMill
Nanobiotix S.A.Sponsored ADR (NASDAQ:NBTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Gap DownHere's What Happened - MarketBeat
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology - ChartMill
Nanobiotix H2 Earnings Call Highlights - Yahoo Finance
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026 - ChartMill
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process - Benzinga
NANOBIOTIX Statement Regarding Recent Media Speculation - ChartMill
Nanobiotix (NASDAQ:NBTX) Shares Gap UpShould You Buy? - MarketBeat
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Benzinga
Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Nanobiotix (NASDAQ:NBTX) Hits New 1-Year HighShould You Buy? - MarketBeat
Nanobiotix (NASDAQ:NBTX) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Nanobiotix (NASDAQ:NBTX) Sets New 52-Week HighWhat's Next? - MarketBeat
Short Interest in Nanobiotix S.A.Sponsored ADR (NASDAQ:NBTX) Grows By 114.9% - MarketBeat
NANOBIOTIX to Participate in Investor Conferences in March - ChartMill
Nanobiotix (NASDAQ:NBTX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Gap Up Following Analyst Upgrade - Defense World
Nanobiotix (NASDAQ:NBTX) Shares Gap Up After Analyst Upgrade - MarketBeat
Nanobiotix (NASDAQ:NBTX) Stock Price Up 5.8% – Here’s What Happened - Defense World
Nanobiotix (NASDAQ:NBTX) Shares Up 5.8%Should You Buy? - MarketBeat
Looking Into Nanobiotix SA's Recent Short Interest - Sahm
Nanobiotix (NASDAQ:NBTX) Stock Price Down 6.2%Here's What Happened - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Here’s Why - Defense World
Nanobiotix (NASDAQ:NBTX) Trading Up 3.3% – Time to Buy? - Defense World
Nanobiotix (NASDAQ:NBTX) Stock Price Up 3.3%Time to Buy? - MarketBeat
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Nanobiotix (NASDAQ:NBTX) Shares Up 5%What's Next? - MarketBeat
Preferred dividends of Nanobiotix SA Sponsored ADR – LS:A2QKZM - TradingView
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives $11.00 Consensus Price Target from Analysts - Defense World
Leerink Partnrs Decreases Earnings Estimates for Nanobiotix - Defense World
나노바이오틱스 (NBTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):